PR.com: Business Directory, Press Releases, Jobs, Products, Services, Articles
 
Businesses Articles Press Releases Follow @PRcom
Press Release Pricing | News by Category | News by Country | News by US Region | Recent News | PR.com News on Your Site
 

Press Releases

 

AnaSpec, EGT Group

Press Release


Receive press releases from AnaSpec, EGT Group: By Email RSS Feeds:
Discover the Next IDE Inhibitor with the Newly Launched SensoLyte® IDE Activity Assay

AnaSpec Launches Industry’s First FRET-based Assay for Measurement of Insulin Degrading Enzyme (IDE) Activity for inhibitor high throughput screening- the SensoLyte® 520 IDE Activity Assay Kit.

Fremont, CA, June 12, 2014 --(PR.com)-- Discover your next Insulin Degrading Enzyme (IDE) inhibitor by using the newly launched SensoLyte® 520 IDE activity assay from AnaSpec. This is the first FRET-based (Ex/Em=490/520 nm) IDE assay that is commercially available and can be used for high-throughput screening (HTS) of IDE inhibitor lead compounds. The highly sensitive substrate used in the assay can detect as low as 0.8 ng/ml active IDE and has minimal cross reaction with Neprilysin, TACE, b-Secretase, ADAM10 and BACE2.

Insulin degrading enzyme (IDE), an extremely conserved Zn2+ metalloendopeptidase, belongs to the M16A metallopeptidase family (1-3). IDE is expressed in almost all tissues and distributed in the cytosol. It degrades various substrates such as insulin, IGF-II, TGF-α, glucagon, amylin, calcitonin, β-amyloid and amyloid precursor protein (APP) (4-6). Growing evidence has indicated that IDE may be involved in the pathogenesis of Alzheimer's disease and diabetes mellitus type 2 (2, 7, 8).

For more information, please visit: https://www.anaspec.com/products/promotions.asp?id=125&col=2&row=1

References
1. Fernández-Gamba, A. et al. Curr Pharm Des 15, 3644 (2009).
2. McCord, LA. et al. Proc Natl Acad Sci USA 110, 13827 (2013).
3. de Tullio, MB. et al. Prion 2, 51 (2008).
4. Edbauer, D. et al. J Biol Chem 277, 13389 (2002).
5. Morelli, L. et al. Biochem Biophys Res Commun 332, 808 (2005).
6. Kurochkin, IV. Trends Biochem Sci 26, 421 (2001).
7. Delledonne, A. et al. Mol Neurodegener 4, 39 (2009).
8. Zhao, J. et al. Mol Neurodegener 4, 4 (2009).

AnaSpec, EGT Group
AnaSpec, EGT Group is a leading provider of integrated proteomics and genomics solutionsTM for worldwide life science research. AnaSpec offers expertise in peptides, detection reagents, antibodies, assay kits, amino acids, oligonucleotides, and Takyon™ qPCR MasterMixes. AnaSpec carries a broad product line of biochemicals and reagents for basic research, high-throughput screening (HTS) and drug discovery. AnaSpec also provides premier custom services including peptide synthesis, antibody production, assay development, fluorescent dyes, and oligonucleotide synthesis. AnaSpec is certified to ISO 9001:2008.

For more information visit: www.anaspec.com
Contact Information
AnaSpec, Inc.
Cecilia Po
510-791-9560
Contact
www.anaspec.com

Click here to view the list of recent Press Releases from AnaSpec, EGT Group
Promote Your Business